Profil
Mr. Paul A. Howard is Founding Partner at Mediphase Venture Partners.
He is on the Board of Directors at Serenex, Inc.
Mr. Howard was a Senior Vice President at Hambrecht & Quist Capital Management in Boston from 1992-1999, where he was responsible for managing the fund's biotechnology investments.
From 1983-1990, he was a Senior Technical Sales Executive for the Miles Biotechnology Division of Bayer A.G.
Mr. Howard earned an AB from Bowdoin College in 1981, an MS from the University of Massachusetts, Amherst in 1983, and an S.M.
from the Sloan School of Management at M.I.T.
in 1992.
He serves on the Board of Directors of Supplemental Health Care and Serenex.
Postes actifs de Paul A. Howard
| Sociétés | Poste | Début |
|---|---|---|
Limulus Management Co. LLC
Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co LLC invests in healthcare/life science companies located in the US. The firm focuses on companies with intellectual property positions and growth potential. It targets companies operating in the fields of biopharmaceutical technology and life sciences information. It provides financing for early stage capital requirements with an investment size ranging from $4 to $8 million. | Fondateur | 03/01/2011 |
Wellpartner LLC
Wellpartner LLC Medical DistributorsDistribution Services Provides pharmacy distribution solutions and contract pharmacy administration services | Directeur/Membre du Conseil | - |
Anciens postes connus de Paul A. Howard
| Sociétés | Poste | Fin |
|---|---|---|
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries. | Gestionnaire de Portefeuille-Actions | 31/12/1998 |
Bayer AG /Plasma Products Business/
Bayer AG /Plasma Products Business/ Pharmaceuticals: MajorHealth Technology Provides plasma products | Corporate Officer/Principal | 31/12/1989 |
| TETRAPHASE PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | - |
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops drugs | Directeur/Membre du Conseil | - |
Formation de Paul A. Howard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops drugs | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries. | Finance |
Wellpartner LLC
Wellpartner LLC Medical DistributorsDistribution Services Provides pharmacy distribution solutions and contract pharmacy administration services | Distribution Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Bowdoin College
Bowdoin College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer AG /Plasma Products Business/
Bayer AG /Plasma Products Business/ Pharmaceuticals: MajorHealth Technology Provides plasma products | Health Technology |
University of Massachusetts
University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Limulus Management Co. LLC
Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co LLC invests in healthcare/life science companies located in the US. The firm focuses on companies with intellectual property positions and growth potential. It targets companies operating in the fields of biopharmaceutical technology and life sciences information. It provides financing for early stage capital requirements with an investment size ranging from $4 to $8 million. | Finance |
















